AR058397A1 - Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos - Google Patents
Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismosInfo
- Publication number
- AR058397A1 AR058397A1 ARP060105602A ARP060105602A AR058397A1 AR 058397 A1 AR058397 A1 AR 058397A1 AR P060105602 A ARP060105602 A AR P060105602A AR P060105602 A ARP060105602 A AR P060105602A AR 058397 A1 AR058397 A1 AR 058397A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- unsubstituted
- atom
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de alquilfosfolípidos con citotoxicidad reducida que son, de utilidad para el tratamiento de diversas enfermedades y/o afecciones fisiopatologicas en mamíferos, preferentemente seres humanos, que son causadas por microorganismos, en particular bacterias, hongos, protozoos y/o virus. Dichos alquilfosfolípidos se pueden emplear como drogas individuales o en. transcurso de terapias combinadas y también se pueden usar para el tratamiento de tumores. Reivindicacion 1: Uso de un derivado alquilfosfolípido caracterizado porque responde a la formula (1), en donde W, X, Y se seleccionan de manera independiente del grupo formado por un átomo de oxígeno, un átomo de azufre; R1 es -[(CR3R4)-Z]-R5; R2 es -(CR6R7)-R8; R3 y R4 se seleccionan, de manera independiente, del grupo formado por un átomo de hidrogeno; alquilo C1-12 sustituido o no sustituido, (alquil C1-12)q-A-(alquilo C1-12)r sustituido o no sustituido, -OH, -C(O)-(alquilo C8-30) sustituido o no sustituido, -OC(O)- (alquilo C8-30) sustituido o no sustituido, -NHCO-(alquilo C1-12) sustituido o no sustituido, -N(alquil C1-12)CO-(alquilo C1-12) sustituido o no sustituido; u opcionalmente R3 y R4 forman juntos un sistema de anillos sustituido o no sustituido saturado, parcialmente insaturado o aromático heterocíclico de 3, 4, 5, 6, 7 u 8 átomos de anillo que contiene al menos un heteroátomo seleccionado del grupo formado por: un átomo de oxígeno, un átomo de azufre; R5 se selecciona, de manera independiente, del grupo formado por alquilo C8-30 sustituido o no sustituido, - C(O)-(alquilo C8-30) sustituido o no sustituido, un grupo esteroide sustituido o no sustituido; R6 y R7 se seleccionan, de manera independiente, del grupo formado por un átomo de hidrogeno, -OH, un átomo de halogeno, -F, -Cl, -Br, -I, -CN, alquilo C1-6, -CF3, -N3, -NH2, -NO2, -OCF3, -SH; u opcionalmente R6 y R7 forman juntos un sistema de anillos sustituido o no sustituido saturado, parcialmente insaturado o aromático de 3, 4, 5, 6 o 7 átomos de carbono; u opcionalmente si p es 1, -(CR6R7)p- también puede ser un sistema de anillos sustituido o no sustituido saturado, parcialmente insaturado o aromático de 3, 4, 5, 6 o 7 átomos de carbono formados junto con R6 y R7; R8 se selecciona del grupo formado por -VR9R10R11; un heterociclo sustituido o no sustituido, donde el heterociclo es (i) un sistema de anillos de átomos de carbono monocíclico saturado, parcialmente insaturado o aromático de 5, 6 o 7 miembros con al menos un heteroátomo seleccionado del grupo formado por un átomo de nitrogeno, un átomo de oxígeno, un átomo de azufre, un átomo de arsénico, y con la condicion que al menos un heteroátomo es un átomo de nitrogeno cuaternario o un átomo de arsénico cuaternario, o (ii) un sistema de anillos de átomos de carbono bicíclico saturado, parcialmente insaturado o aromático de 7, 8, 9, 10, 11 o 12 miembros con al menos un heteroátomo seleccionado del grupo formado por un átomo de nitrogeno, un átomo de oxígeno, un átomo de azufre, un átomo de arsénico, y con la condicion que al menos un heteroátomo es un átomo de nitrogeno cuaternario o un átomo de arsénico cuaternario, o (iii) un grupo tropina, donde dos o más átomos del anillo heterocíclico se pueden unir además a través de un puente alquileno y donde, si el heterociclo está sustituido, está sustituido con al menos un radical R12, que en el caso de dos o más radicales R12 son, de manera independiente, idénticos entre sí, parcialmente idénticos o diferentes; R9, R10, R11, R12 se seleccionan, de manera independiente, del grupo formado por un átomo de hidrogeno, alquilo C1-18 sustituido o no sustituido, cicloalquilo C3-8 sustituido o no sustituido, (alquil C1- 12)s-B-(alquil C1-12)t-C-(alquilo C1-12)u sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, alcoxi sustituido o no sustituido, -OH, halogeno, -F, -Cl, -Br, -I, =O, -C(O)O-(alquilo C1-12), -C(O)O- (cicloalquilo C3-8), -C(O)O-arilo, -C(O)O-heteroarilo, -C(O)O-heterociclilo, -C(O)-(alquilo C1-12), -C(O)-(cicloalquilo C3-8), -C(O)-arilo, -C(O)-heteroarilo, -C(O)-heterociclilo y opcionalmente dos sustituyentes R12 pueden formar juntos un sistema de anillos sustituido o no sustituido saturado, parcialmente insaturado o aromático de 3, 4, 5, 6 o 7 átomos de carbono; Z se selecciona, de manera independiente, del grupo formado por un átomo de oxígeno; un átomo de azufre; V se selecciona, de manera independiente, del grupo formado por un átomo de nitrogeno, un átomo de arsénico; A, B, C se seleccionan, de manera independiente, del grupo formado por un átomo de oxígeno; un átomo de azufre; S(O)2; m es, de manera independiente, 1, 2 o 3; n es, de manera independiente, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 o 10 y preferentemente es 0, 1, 2 o 3; p es, de manera independiente, 0, 1, 2, 3, 4, 5 o 6, y preferentemente es 0, 1, 2 o 3; q, r, s, t, u son, de manera independiente entre sí, 0 o 1; para la elaboracion de un medicamento para el tratamiento o la profilaxis de las enfermedades y/o afecciones fisiopatologicas en mamíferos que son causadas por microorganismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75143805P | 2005-12-19 | 2005-12-19 | |
EP05027823A EP1800684A1 (en) | 2005-12-20 | 2005-12-20 | Novel alkyl phospholipid derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058397A1 true AR058397A1 (es) | 2008-01-30 |
Family
ID=37942171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105602A AR058397A1 (es) | 2005-12-19 | 2006-12-19 | Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1962862B1 (es) |
JP (1) | JP5232009B2 (es) |
KR (1) | KR101378005B1 (es) |
AR (1) | AR058397A1 (es) |
AU (1) | AU2006328479B2 (es) |
CA (1) | CA2632449A1 (es) |
HK (1) | HK1124775A1 (es) |
IL (1) | IL191695A (es) |
NO (1) | NO20082862L (es) |
PL (1) | PL1962862T3 (es) |
RU (1) | RU2469727C2 (es) |
UY (1) | UY30042A1 (es) |
WO (1) | WO2007071658A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2097081A1 (en) * | 2006-12-08 | 2009-09-09 | Jado Technologies GmbH | Cholesterylamines for the treatment and prevention of infectious diseases |
DE102007014375A1 (de) * | 2007-03-26 | 2008-10-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Oleylphosphocholin |
AT505515B1 (de) * | 2007-08-02 | 2009-04-15 | Orphanidis Pharma Res | Verwendung von miltefosin zur herstellung eines medikaments zur behandlung der cryptosporidiose beim menschen |
WO2009090063A1 (en) * | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
WO2010020276A1 (en) * | 2008-08-19 | 2010-02-25 | Orphanidis Pharma Research Gmbh | Treatment of coccidian parasites |
US20130345177A1 (en) * | 2011-03-04 | 2013-12-26 | Dafra Pharma Research & Development Bvba | Oleyl Phosphocholine for the Treatment of Mycosis |
CN102584926B (zh) * | 2012-01-12 | 2014-10-15 | 浙江大学 | 利用基于胆固醇和磷酸胆碱两亲小分子制备超分子水凝胶的方法 |
RU2487708C1 (ru) * | 2012-03-12 | 2013-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | Способ лечения парвовирусной инфекции в19 у детей раннего возраста |
CN114656378A (zh) | 2016-05-16 | 2022-06-24 | 得克萨斯州大学系统董事会 | 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质 |
EP3684180A4 (en) * | 2017-09-21 | 2021-07-07 | The Scripps Research Institute | NEW THERAPIES FOR THE TREATMENT AND PREVENTION OF CHRONIC RHINOSINUSITIS |
ES2739773B2 (es) * | 2018-08-02 | 2020-11-17 | Univ Alicante | Compuestos zwitterionicos de acidos 2-fosfocolina carboxilicos y su uso como agentes citotoxicos |
AU2020395150A1 (en) * | 2019-12-02 | 2022-06-23 | AliquantumRx, Inc. | Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5984824A (ja) * | 1982-11-08 | 1984-05-16 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
IE59778B1 (en) | 1985-12-04 | 1994-04-06 | Max Planck Gesellschaft | Medicament with anti-tumour action containing hexadecylphosphocholine |
CN1017435B (zh) | 1987-03-24 | 1992-07-15 | 日本化学医药株式会社 | 新的甘油衍生物的制备方法 |
DE3942933A1 (de) * | 1989-12-23 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate |
DE4111105A1 (de) * | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | Neue erucyl-, brassidyl- und nervonylderivate |
DE4219972A1 (de) * | 1991-07-04 | 1993-01-07 | Asta Medica Ag | Arzneimittel mit antineoplastischer wirkung enthaltend als wirkstoff octadecyl-(2-(n-methylpiperidino)-ethyl)-phosphat und verfahren zu dessen herstellung |
DE4132344A1 (de) | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis |
US6254879B1 (en) | 1991-09-27 | 2001-07-03 | Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. | Methods of treating protozoal diseases |
FR2683915A1 (fr) * | 1991-11-18 | 1993-05-21 | Philips Electronique Lab | Appareil d'examen de milieux par echographie ultrasonore. |
DE4222910A1 (de) | 1992-07-11 | 1994-01-13 | Asta Medica Ag | Neue Phospholipidderivate |
US6172050B1 (en) | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
DE4233044A1 (de) | 1992-10-01 | 1994-04-07 | Asta Medica Ag | Phospholipidderivate, die höhere Elemente der V. Hauptgruppe enthalten |
US5958906A (en) | 1992-10-01 | 1999-09-28 | Asta-Medica Aktiengesellschaft | Phospholipid derivatives containing higher elements of the fifth main group |
DE19650778C2 (de) | 1996-12-06 | 2001-01-04 | Asta Medica Ag | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
JP3367892B2 (ja) * | 1997-05-22 | 2003-01-20 | 株式会社ヨシツカ精機 | 多段粉末成形プレス |
DE19835611A1 (de) * | 1998-08-06 | 2000-02-10 | Max Planck Gesellschaft | Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten |
ES2185418T3 (es) | 1998-12-04 | 2003-04-16 | Max Delbrueck Centrum | Agentes previstos para tratar tumores, basados en liposomas y que contienen tamoxifeno. |
US6521879B1 (en) | 2001-04-20 | 2003-02-18 | Rockwell Collins, Inc. | Method and system for controlling an LED backlight in flat panel displays wherein illumination monitoring is done outside the viewing area |
DE10148067A1 (de) * | 2001-09-28 | 2003-04-17 | Max Planck Gesellschaft | Hitzesterilisierbare Alkylphosphocholin-Liposome |
AU2003235686A1 (en) * | 2002-01-14 | 2003-07-30 | Dow Global Technologies Inc. | Drug nanoparticles from template emulsions |
DE10203195A1 (de) * | 2002-01-25 | 2003-08-07 | Zentaris Ag | Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen |
US7887817B2 (en) * | 2002-01-25 | 2011-02-15 | Aeterna Zentaris Gmbh | Process for preventing protozoal diseases |
ES2536710T3 (es) * | 2002-03-25 | 2015-05-27 | Arimed Inc. | Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A |
KR20110102485A (ko) * | 2002-07-30 | 2011-09-16 | 아에테르나 젠타리스 게엠베하 | 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품 |
CN1742017A (zh) * | 2002-10-30 | 2006-03-01 | Mak科学公司 | 抗原生动物的环取代的磷脂 |
WO2006081452A2 (en) * | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
WO2006122716A1 (en) * | 2005-05-18 | 2006-11-23 | Heidelberg Pharma Gmbh | Use of ether-linked lysophosphatidylcholines and alkylphosphocholines for the treatment of papilloma virus induced warts and sarcoids |
-
2006
- 2006-12-19 JP JP2008546419A patent/JP5232009B2/ja not_active Expired - Fee Related
- 2006-12-19 CA CA002632449A patent/CA2632449A1/en not_active Abandoned
- 2006-12-19 KR KR1020087017671A patent/KR101378005B1/ko active IP Right Grant
- 2006-12-19 AU AU2006328479A patent/AU2006328479B2/en not_active Ceased
- 2006-12-19 WO PCT/EP2006/069873 patent/WO2007071658A2/en active Application Filing
- 2006-12-19 UY UY30042A patent/UY30042A1/es not_active Application Discontinuation
- 2006-12-19 PL PL06847032T patent/PL1962862T3/pl unknown
- 2006-12-19 AR ARP060105602A patent/AR058397A1/es unknown
- 2006-12-19 RU RU2008129597/15A patent/RU2469727C2/ru not_active IP Right Cessation
- 2006-12-19 EP EP06847032.7A patent/EP1962862B1/en active Active
-
2008
- 2008-05-26 IL IL191695A patent/IL191695A/en not_active IP Right Cessation
- 2008-06-23 NO NO20082862A patent/NO20082862L/no not_active Application Discontinuation
-
2009
- 2009-03-12 HK HK09102356.5A patent/HK1124775A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL191695A0 (en) | 2009-02-11 |
EP1962862B1 (en) | 2013-09-04 |
JP5232009B2 (ja) | 2013-07-10 |
AU2006328479B2 (en) | 2012-03-08 |
AU2006328479A1 (en) | 2007-06-28 |
HK1124775A1 (en) | 2009-07-24 |
JP2009519999A (ja) | 2009-05-21 |
UY30042A1 (es) | 2007-07-31 |
KR20080081326A (ko) | 2008-09-09 |
WO2007071658A3 (en) | 2007-10-04 |
NO20082862L (no) | 2008-08-27 |
WO2007071658A2 (en) | 2007-06-28 |
KR101378005B1 (ko) | 2014-03-27 |
IL191695A (en) | 2013-12-31 |
CA2632449A1 (en) | 2007-06-28 |
RU2008129597A (ru) | 2010-01-27 |
RU2469727C2 (ru) | 2012-12-20 |
PL1962862T3 (pl) | 2014-01-31 |
EP1962862A2 (en) | 2008-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058397A1 (es) | Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos | |
ECSP066669A (es) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, y 1,2-benzisotiazoles, y preparación y usos de los mismos | |
AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
AR085908A1 (es) | DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK) | |
AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
PA8791601A1 (es) | Compuestos de biciclolactama sustituida | |
UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
UY29795A1 (es) | Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
TW200833329A (en) | 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
AR066142A1 (es) | IMIDAZOTRIAZINAS E IMIDAZOPIRIMIDINAS COMO INHIBIDORES DE QUINASA, UNA COMPOSICION QUE LAS INCLUYE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LA DESREGULACIoN DE LA VIA DE SENALIZACIoN HGF/C-MET | |
SV2007002397A (es) | Aminopiridinas como inhibidores de b-secretasa ref. am101663 | |
NI201100050A (es) | Derivados amida de heteroarilos su uso como activadores de glucoquinasa. | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR056470A1 (es) | Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa | |
AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
AR049539A1 (es) | Quinolina-tiazolinonas | |
AR058377A1 (es) | Derivados de pirroliltriazina, procedimientos para su obtencion y formulacion cosmetica y farmaceutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |